Why Cell and Gene Therapy CDMOs Are Becoming Strategic Partners, Not Just Service Providers
The CDMO relationship in cell and gene therapy is evolving fast. Here's what business leaders need to understand before the next inflection point.
For years, contract development and manufacturing organizations played a supporting role in biopharma. In cell and gene therapy, that dynamic is changing fundamentally. CDMOs are no longer simply fulfilling orders — they are co-shaping the commercial viability of entire therapeutic programs.
The complexity of manufacturing living biologics demands a depth of process expertise that most sponsors cannot build in-house at speed. Vector production, cell expansion, cryopreservation logistics — each step carries compounding risk. Sponsors are increasingly selecting CDMO partners early in development, treating them as strategic extensions of their own R&D infrastructure rather than transactional vendors.
Capacity constraints remain a persistent pressure point. Demand from a growing pipeline of clinical-stage programs continues to outpace available GMP manufacturing slots globally. This imbalance is reshaping commercial negotiations and pushing sponsors to commit earlier and lock in longer-term agreements.
Geography is also gaining strategic weight. Regulatory divergence across key markets, combined with supply chain resilience priorities, is prompting developers to reconsider single-site manufacturing dependencies. Regional CDMO footprints are becoming a differentiator, not just a convenience.
Nexvora Intelligence has published a dedicated intelligence report examining the global Cell and Gene Therapy CDMO market in depth — covering competitive positioning, capacity trends, partner selection criteria, and the strategic forces reshaping this space. Business leaders navigating this landscape will find the analysis directly relevant to partnership decisions and commercial planning.